期刊文献+

2007年山西省太原市健康人群乙型病毒性肝炎免疫水平监测分析 被引量:5

Surveillance on immunity level of hepatitis B in healthy population in Taiyuan city,Shanxi province,2007
原文传递
导出
摘要 目的了解太原市健康人群乙型病毒性肝炎(乙肝,hepatitis B)表面抗原抗体水平,为降低人群乙肝感染率及制定相应防制措施提供一定依据。方法根据《全国人群乙肝等有关疾病血清学调查方案》的要求,结合太原市具体情况,采用按容量比例概率抽样法(PPS)在全市随机抽取3~59岁常住人口,采用酶联免疫吸附实验(ELISA)检测乙肝表面抗原及抗体。结果太原市健康人群乙肝表面抗原阳性率为1.5%,表面抗体阳性率为44.3%,各县(市、区)有差异;各年龄组间乙肝表面抗原阳性率及抗体阳性率差异有统计学意义;男女性别间免疫水平差异无统计学意义;不同职业和不同免疫史人群间免疫水平存在差异。结论接种乙肝疫苗是预防乙肝最有效的措施。太原市健康人群乙肝表面抗体水平较低,应针对性地采取措施,健全管理制度,提高免疫成功率。 Objective To understand the immunity level of hepatitis B in healthy population in Taiyuan and provide evidence for the reduction of infection rate and development of preventive and control measures. Methods According to national serological survey protocol for hepatitis B and other diseases, healthy people aged 3 - 59 years were selected in Taiyuam by probability proportion to size (PPS) sampling. Enzyme linked immunosorbent assay (ELISA) was conducted to detect HBsAg and HBsAb. Results The positive rate of HBsAg was 1.5%, and the positive rate of HBsAb was 44.3% in healthy population, which varied by areas. The differences on HBsAg and HBsAb had statistical significance in different age groups, but had no statistical significance between males and females. There were significant differences on immunity level in people with different occupation and different immunization history. Conclusion hepatitis B vaccination is the most effective measure to prevent hepatitis B. It is suggested to strengthen the management of vaccination and take targeted measures to increase the positive conversion rate of hepatitis B antibody.
出处 《疾病监测》 CAS 2010年第11期891-893,共3页 Disease Surveillance
关键词 肝炎 乙型 抗原 抗体 免疫 监测 hepatitis B antigen antibody immunization surveillance
  • 相关文献

参考文献5

二级参考文献27

  • 1余滨,王夏,韩荣华,陈载超,陈再芳.武汉市近10年1~3岁儿童乙型肝炎疫苗接种率和乙型肝炎病毒表面抗原携带率调查及发病率分析[J].中国计划免疫,2005,11(2):117-119. 被引量:37
  • 2杨晓光,孔灵芝,翟凤英,马冠生,金水高,中国居民营养与健康状况调查技术执行组.中国居民营养与健康状况调查的总体方案[J].中华流行病学杂志,2005,26(7):471-474. 被引量:174
  • 3迮文远.计划免疫学(第2版)[M].上海:上海科学技术文献出版社,2002.66.
  • 4庄辉.乙型肝炎流行病学变迁[EB/OL].http://www.healthoo.com/% 5CA2 % 5C200405 % 5CA22001200405201114230000. asp,2004-5-20./2004-6-13.
  • 5A. Flahault, P. Maison, N. Farran, V. Massari. Six years surveillance of hepatitis A and B in general practice in France[EB/OL] http://www. eurosurveillance, org/em/index - 02. asp? 1g = 2&an = 1997.
  • 6Zhiyong Hong, Shimian Zou, Antonio Giulivi. Hepatitis B and its Control in Southeast Asia and China (J/OL). http://www, hc-sc.gc. ca/pphb-dgspsp/publicat/ccdr-rmtc/gfx/ccdrpg-e, gif.
  • 7段功伟.我国首支治疗性乙肝疫苗问世已进入临床实验[EB/OL].http://www.southcn.com/news/gdnews/gdtodayimportant/200311080104.htm,2003.11.8.
  • 8庄辉.乙型肝炎[A].见:耿贯一 主编.流行病学.第2版[C].北京:人民卫生出版社,1996.721一728.
  • 9Hsu HM, Lu CF, Lee SC, et al. Seroepidemiology surey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immuination. J Infect Dis, 1999,179:367-370.
  • 10WHO.Hepatitis B surface antigen assay: operational characteristics.2000.1-15.

共引文献988

同被引文献39

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部